Modern diabetes practice rests on a handful of trials that defined how we target glucose, blood pressure, and risk. This page maps them for quick clinical reference. Each link opens a concise PICO summary with expert commentary.
Glycaemic control & complications
- DCCT — intensive insulin in type 1 diabetes; the foundational microvascular evidence.
- EDIC — metabolic memory: durable benefit decades later.
- UKPDS 33 — intensive glucose control in newly diagnosed type 2 diabetes.
- UKPDS 34 — metformin: the evidence that made it first-line.
How low to go: the intensive-control safety debate
- ACCORD — harm from targeting HbA1c <6.0% in high-risk patients.
- ADVANCE — nephropathy benefit without the mortality signal.
- VADT — completing the ACCORD/ADVANCE/VADT picture.
Blood pressure & multifactorial risk
Prevention
- Diabetes Prevention Program (DPP) — lifestyle vs metformin.
- DPPOS — durability of prevention at 10 years.
- Look AHEAD — the limits of lifestyle for cardiovascular endpoints.
Browse every summary
Explore the full archives:
Type 2 Diabetes ·
Type 1 Diabetes ·
Prevention ·
Glycaemic Control
Hormone Insight summaries are reviewed by a practicing endocrinologist and are for healthcare professionals. They summarise published evidence and do not constitute medical advice. See our Editorial Guidelines.